OBJECTIVES: To evaluate if povidone-iodine (PVP-I) can be used topically in the treatment of chronic suppurative otitis media-tubotympanic disease and to compare it with ciprofloxacin hydrochloride ear drops. DESIGN: Prospective double-blind randomized study. SETTING:Academic tertiary medical center. PATIENTS: Forty patients with chronic suppurative otitis media were randomized into 2 groups. INTERVENTION: One group (19 patients) received 5% PVP-I ear drops, while the other group (21 patients) received 0.3% ciprofloxacin ear drops. Both were administered topically, 3 drops 3 times daily for 10 days. These patients were followed up at weekly intervals for up to 4 weeks after commencing therapy. RESULTS: Clinical improvement at the end of study was 88% in the PVP-I group and 90% in the ciprofloxacin group. The most commonly isolated organism was Pseudomonas aeruginosa. In vitro resistance to ciprofloxacin was seen in 17% of organisms, while no resistance was seen for PVP-I. CONCLUSIONS: To our knowledge, this is the first study to evaluate the efficacy of PVP-I as a topical agent in the treatment of chronic suppurative otitis media. The results show that clinically, topical PVP-I is as effective as topical ciprofloxacin, with a superior advantage of having no in vitro drug resistance. Also, there is an added benefit of reduced cost of therapy.
RCT Entities:
OBJECTIVES: To evaluate if povidone-iodine (PVP-I) can be used topically in the treatment of chronic suppurative otitis media-tubotympanic disease and to compare it with ciprofloxacin hydrochloride ear drops. DESIGN: Prospective double-blind randomized study. SETTING: Academic tertiary medical center. PATIENTS: Forty patients with chronic suppurative otitis media were randomized into 2 groups. INTERVENTION: One group (19 patients) received 5% PVP-I ear drops, while the other group (21 patients) received 0.3% ciprofloxacin ear drops. Both were administered topically, 3 drops 3 times daily for 10 days. These patients were followed up at weekly intervals for up to 4 weeks after commencing therapy. RESULTS: Clinical improvement at the end of study was 88% in the PVP-I group and 90% in the ciprofloxacin group. The most commonly isolated organism was Pseudomonas aeruginosa. In vitro resistance to ciprofloxacin was seen in 17% of organisms, while no resistance was seen for PVP-I. CONCLUSIONS: To our knowledge, this is the first study to evaluate the efficacy of PVP-I as a topical agent in the treatment of chronic suppurative otitis media. The results show that clinically, topical PVP-I is as effective as topical ciprofloxacin, with a superior advantage of having no in vitro drug resistance. Also, there is an added benefit of reduced cost of therapy.
Authors: Rahul Mittal; Christopher V Lisi; Robert Gerring; Jeenu Mittal; Kalai Mathee; Giri Narasimhan; Rajeev K Azad; Qi Yao; M'hamed Grati; Denise Yan; Adrien A Eshraghi; Simon I Angeli; Fred F Telischi; Xue-Zhong Liu Journal: J Med Microbiol Date: 2015-08-05 Impact factor: 2.472
Authors: Lee-Yee Chong; Karen Head; Katie E Webster; Jessica Daw; Peter Richmond; Tom Snelling; Mahmood F Bhutta; Anne Gm Schilder; Martin J Burton; Christopher G Brennan-Jones Journal: Cochrane Database Syst Rev Date: 2021-02-09
Authors: Christopher G Brennan-Jones; Karen Head; Lee-Yee Chong; Martin J Burton; Anne Gm Schilder; Mahmood F Bhutta Journal: Cochrane Database Syst Rev Date: 2020-01-02
Authors: Karen Head; Lee-Yee Chong; Mahmood F Bhutta; Peter S Morris; Shyan Vijayasekaran; Martin J Burton; Anne Gm Schilder; Christopher G Brennan-Jones Journal: Cochrane Database Syst Rev Date: 2020-01-06
Authors: Karen Head; Lee-Yee Chong; Mahmood F Bhutta; Peter S Morris; Shyan Vijayasekaran; Martin J Burton; Anne Gm Schilder; Christopher G Brennan-Jones Journal: Cochrane Database Syst Rev Date: 2020-01-06